Douglas D. Taylor is an entrepreneur and former academic researcher in the field of extracellular vesicles.

Taylor attained a bachelor's degree from the University of Richmond and a Ph.D. from Wake Forest University. He was a post-doctoral fellow at Boston University.[1] Taylor was a professor and Vice Chair for Research in the Department of Obstetrics, Gynecology, and Women's Healthheld at the University of Louisville in Kentucky.[1] He was also on the faculty of the University of California, Davis.[2] From 2013 to 2015, he was the Chief Scientific Officer of Aethlon Medical's wholly owned subsidiary, Exosome Sciences.[3][4]

Taylor first described exosomes in the 1980s, originally believing them to be cell fragments.[5] He later wrote that exosomes could potentially be used as biomarkers for profiling in ovarian cancer biopsies, and could extend their utility to screening other asymptomatic areas.[6] What constitutes exosomes has not been defined; specifically, markers of exosomes do not exist.[7]

In 2015, the Journal of Immunology retracted a paper it published in 2006 and which Taylor had co-written[8] after an "institutional research misconduct investigation committee determined that multiple figures in the...paper were falsified".[9][10] Taylor responded to the retraction on the blog Retraction Watch, disputing various aspects of the retraction, and stating that he sent "copies of the original data so that the [journal's] editor could independently verify that no falsification or fabrication occurred".[10]

References

  1. 1 2 "Aethlon Medical Appoints Douglas Taylor to Exosome Sciences Advisory Board". PR Newswire (Press release). Retrieved August 31, 2016.
  2. ↑ UC Davis Health System, Department of Public Affairs and Marketing. "UC Davis Health System Feature Story: Cancer in the crosshairs". ucdavis.edu. Retrieved 15 July 2015.
  3. ↑ "Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc". PR Newswire (Press release). Retrieved August 31, 2016.
  4. ↑ "Executive Team". Exosome Sciences. Archived from the original on August 17, 2015. Retrieved March 3, 2016.
  5. ↑ Todd S. Ing, et al, Dialysis: History, Development and Promise (Hackensack, New Jersey: World Scientific Publishing, 2012), p. 843
  6. ↑ Taylor, Douglas (July 2008). "MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer". Gynecologic Oncology. 110 (1): 13–21. doi:10.1016/j.ygyno.2008.04.033. PMID 18589210.
  7. ↑ Edgar, James (2016). "Q&A: What are exosomes, exactly?". BMC Biology. 14 (1): 46. doi:10.1186/s12915-016-0268-z. PMC 4906597. PMID 27296830.
  8. ↑ Taylor, DD; Akyol, S; Gercel-Taylor, C (2006). "Pregnancy-associated exosomes and their modulation of T cell signaling". J Immunol. 176 (3): 1534–42. doi:10.4049/jimmunol.176.3.1534. PMID 16424182.
  9. ↑ "Retraction: Pregnancy-Associated Exosomes and Their Modulation of T Cell Signaling," Journal of Immunology, June 15, 2015, vol. 194 no. 12 6190.(subscription required)
  10. 1 2 Bernès, Sylvain (June 10, 2015). "Exosome pioneer's paper retracted after investigation finds "multiple" faked figures". Retraction Watch. Retrieved January 7, 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.